

## Special Issue

# Human Extracellular Matrix in Homeostasis and Pathology

### Message from the Guest Editors

It is well established that complex intercellular interactions, as well as biomolecular and biomechanical cues from the extracellular matrix, dictate the growth and maintenance of all tissues through bidirectional signaling, mediated by the physical properties of the ECM along with its biochemical composition. Many cell culture models, including ex vivo organoids, have improved our understanding of ECM development and homeostasis; however, they do not replicate the complex microenvironment of the native ECM across individual tissue types. This Special Issue aims to explore current efforts used to bridge this gap in knowledge across multiple disciplines, including cell biology, genomics, biomechanical and biophysical characterisation, 3D cell culture, and bioengineered smart materials.

### Guest Editors

Dr. Larisa M. Haupt

Centre for Genomics and Personalised Health, Genomics Research Centre, School of Biomedical Sciences, Max Planck Queensland Centre, Queensland University of Technology (QUT), Queensland, 60 Musk Ave., Kelvin Grove, Brisbane, QLD 4059, Australia

Dr. Amaia Cipitria

Ikerbasque Research Associate, Leader of the Bioengineering in Regeneration and Cancer Group, Biodonostia Health Research Institute, Paseo Doctor Beguiristain s/n, 200014 San Sebastián, Spain

### Deadline for manuscript submissions

closed (30 September 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/128756](https://mdpi.com/si/128756)

*Biomedicines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).